Company profile
Axol Bioscience. Human iPSCs for better human disease models.
At Axol Bioscience we use iPSCs to build more relevant models of human disease to expand your understanding and de-risk drug development.
Updated 06 Jun 2026 16:52
Reference milestones and recent Companies House filing stream events.
Next accounts due date
Next confirmation statement due date
Last confirmation statement made up date
Last accounts made up date
AA | Transaction MzQzNzQ4MzE2MWFkaXF6a2N4 | Paper/PDF filed
Published 02 Oct 2024 06:16
CS01 | Transaction MzQzNjAyMTQ2MGFkaXF6a2N4
Published 16 Sep 2024 14:49
Company registered at Companies House
1 Nov 2018 to 31 Jul 2019
"In the UK today, over 1.2 million people suffer from Chronic Obstructive Pulmonary Disease (COPD) which costs the NHS over £1.5 billion. Patients suffering from COPD are unable to empty air out of their lungs because their airways have been narrowed, mainly due to bronchitis and emphysema. The disease profoundly limits the quality of life of its suffers....
1 Jun 2017 to 31 May 2019
The typical patient diagnosed with Glioblastoma multiforme (GBM), which constitutes 45% of all malignant primary brain and CNS tumours, is aged 50-60 and will survive 15 months after diagnosis. The Patient Derived iPSCs for High Grade Glioma (PDi:HGG) project will provide a new strategy for researchers to develop treatments specifically for this cancer. I...
1 Jul 2013 to 30 Jun 2014
Human liver hepatocytes are extremely valuable cells both for drug development laboratories and for patients whose own livers have become damaged either through viral infections, poor diet and/or long term excessive alcohol consumption. There is already a shortage of donor livers for transplantation and this is set to worsen in the future as liver failure...
1 Feb 2012 to 30 Sep 2015
The consortium of Altrika, the University of Edinburgh’s School of Chemistry, Roslin Cellab and Barts and The London bring R&D, manufacturing, clinical and commercialisation experience to the challenge of tracking clinically relevant cell populations in vitro and in vivo. The absence of an in vivo tracking methodology leads to R&D, manufacturing and clini...
